CompletedNot Applicable

Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)

Japan428 participantsStarted 2019-03-18

Plain-language summary

To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against Crohn's disease or ulcerative colitis under actual status of use.

Who can participate

Age range0 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with Crohn's disease or ulcerative colitis who started treatment with this drug * Patients who received this drug for the first time at the medical institution after the day of launch of this drug.

What they're measuring

Number of Participants With Adverse Drug Reactions

Timeframe: 30 weeks from the day of initial dose

Trial details

NCT IDNCT03884439

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-02-02

Results submitted2025-01-17

View on ClinicalTrials.gov More Crohn's Disease trials